Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SenzaGen AB's Enterprise Value is €13.69 Mil.
SenzaGen AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.38 Mil. Therefore, SenzaGen AB's EV-to-FCF for today is -9.95.
The historical rank and industry rank for SenzaGen AB's EV-to-FCF or its related term are showing as below:
FRA:26S'
s EV-to-FCF Range Over the Past 10 Years
Min: -36.72 Med: -10.85 Max: -6.71
Current: -10.21
During the past 11 years, the highest EV-to-FCF of SenzaGen AB was -6.71. The lowest was -36.72. And the median was -10.85.
FRA:26S's EV-to-FCF is ranked worse than 100% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.57
vs FRA:26S: -10.21
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SenzaGen AB's PE Ratio (TTM) for today is calculated as:
SenzaGen AB's share price for today is €0.472.
SenzaGen AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.042.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SenzaGen AB EV-to-FCF Related Terms
SenzaGen AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for SenzaGen AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, SenzaGen AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SenzaGen AB EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where SenzaGen AB's EV-to-FCF falls into.
SenzaGen AB's current Enterprise Value is €13.69 Mil.
SenzaGen AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SenzaGen AB (FRA:26S) has a EV-to-FCF of -9.95 as of Jul. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on SenzaGen AB and its competitors. According to the industry distribution chart, SenzaGen AB ranks #999999 out of 100 companies in the Medical Diagnostics & Research industry.
Is SenzaGen AB's EV-to-FCF too high?
SenzaGen AB's current EV-to-FCF is -9.95. Based on the distribution chart, SenzaGen AB ranks #999999 out of 100 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, SenzaGen AB has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does SenzaGen AB's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SenzaGen AB ranks #999999 out of 100 companies for EV-to-FCF. This places SenzaGen AB in the lower half of its industry. The industry median EV-to-FCF is 26.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.57, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on SenzaGen AB and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SenzaGen AB's current EV-to-FCF is -9.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenzaGen AB stock overvalued right now?
SenzaGen AB (FRA:26S) has a current EV-to-FCF of -9.95. The stock's GF Value™ is €0.57, compared to a current price of €0.47 — trading 17.2% below its estimated fair value. The current EV-to-FCF is -9.95. SenzaGen AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For SenzaGen AB (FRA:26S), the current EV-to-FCF is -9.95 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SenzaGen AB (FRA:26S) Overvalued in 2026?
Based on GuruFocus' analysis, SenzaGen AB stock appears to be undervalued.
The current stock price of €0.47 is trading 17.2% below its estimated GF Value™ of €0.57.
Key valuation signals for FRA:26S:
EV-to-FCF: -9.95
GF Value™: €0.57 vs. price of €0.47 (17.2% below fair value)
No single metric tells the full story. See the FRA:26S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
72GF Score
Get the complete analysis for FRA:26S
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:26S has been successfully added to your 
